266 related articles for article (PubMed ID: 28830378)
1. Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients.
Lee YS; Nam HS; Lim JH; Kim JS; Moon Y; Cho JH; Ryu JS; Kwak SM; Lee HL
BMC Cancer; 2017 Aug; 17(1):557. PubMed ID: 28830378
[TBL] [Abstract][Full Text] [Related]
2. Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion.
Takeuchi E; Okano Y; Machida H; Atagi K; Kondou Y; Kadota N; Hatakeyama N; Naruse K; Shinohara T
Cancer Immunol Immunother; 2022 Feb; 71(2):365-372. PubMed ID: 34170380
[TBL] [Abstract][Full Text] [Related]
3. Important prognostic factors for survival in patients with malignant pleural effusion.
Zamboni MM; da Silva CT; Baretta R; Cunha ET; Cardoso GP
BMC Pulm Med; 2015 Mar; 15():29. PubMed ID: 25887349
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.
Kasapoglu US; Arınç S; Gungor S; Irmak I; Guney P; Aksoy F; Bandak D; Hazar A
Clin Respir J; 2016 Nov; 10(6):791-799. PubMed ID: 25764010
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of a new score using serum alkaline phosphatase and pleural effusion lactate dehydrogenase for patients with malignant pleural effusion.
Shi XY; Yi FS; Wang Z; Qiao X; Zhai K
Thorac Cancer; 2020 Feb; 11(2):320-328. PubMed ID: 31837116
[TBL] [Abstract][Full Text] [Related]
6. Can LENT Prognostic score (LDH, ECOG performance score, blood neutrophil/lymphocyte ratio, tumor type) change the clinical approach in malignant pleural effusion?
Gayaf M; Anar C; Canbaz M; Doğan Bİ; Erbaycu AE; Güldaval F
Tuberk Toraks; 2021 Jun; 69(2):133-143. PubMed ID: 34256503
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance.
Popowicz N; Cheah HM; Gregory C; Miranda A; Dick IM; Lee YCG; Creaney J
PLoS One; 2021; 16(4):e0250628. PubMed ID: 33901252
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in patients with malignant pleural effusion: Is it possible to predict mortality in patients with good performance status?
Abrao FC; Peixoto RD; de Abreu IR; Janini MC; Viana GG; de Oliveira MC; Younes RN
J Surg Oncol; 2016 Apr; 113(5):570-4. PubMed ID: 26751412
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
10. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score.
Clive AO; Kahan BC; Hooper CE; Bhatnagar R; Morley AJ; Zahan-Evans N; Bintcliffe OJ; Boshuizen RC; Fysh ET; Tobin CL; Medford AR; Harvey JE; van den Heuvel MM; Lee YC; Maskell NA
Thorax; 2014 Dec; 69(12):1098-104. PubMed ID: 25100651
[TBL] [Abstract][Full Text] [Related]
11. Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion.
Lim JU; Yeo CD; Kang HS; Park CK; Kim JS; Kim JW; Kim SJ; Lee SH
Sci Rep; 2019 Mar; 9(1):4721. PubMed ID: 30886226
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion.
Lim JU; Yeo CD; Kang HS; Park CK; Kim JS; Kim JW; Kim SJ; Lee SH
PLoS One; 2018; 13(7):e0200341. PubMed ID: 30005083
[TBL] [Abstract][Full Text] [Related]
14. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
[TBL] [Abstract][Full Text] [Related]
15. Differentiating Malignant from Tubercular Pleural Effusion by Cancer Ratio Plus (Cancer Ratio: Pleural Lymphocyte Count).
Verma A; Dagaonkar RS; Marshall D; Abisheganaden J; Light RW
Can Respir J; 2016; 2016():7348239. PubMed ID: 28070157
[No Abstract] [Full Text] [Related]
16. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK
Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic significance of receptor-binding cancer antigen expressed on SiSo cells in lung-cancer-associated pleural effusion.
Yang J; Zhu Y; Wu L; Zhu W; Zhang X; Yang Y; Xu C
Clin Respir J; 2018 Jan; 12(1):279-284. PubMed ID: 27402224
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of the CAIL prognostic score in non-small cell lung cancer patients with malignant pleural effusion.
Li T; Tian P; Huang Q; Zeng H; Wei Q; Li Y
Clin Respir J; 2023 Nov; 17(11):1158-1168. PubMed ID: 37723659
[TBL] [Abstract][Full Text] [Related]
19. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Hsu IL; Su WC; Yan JJ; Chang JM; Lai WW
Lung Cancer; 2009 Sep; 65(3):371-6. PubMed ID: 19157636
[TBL] [Abstract][Full Text] [Related]
20. A laboratory prognostic index model for patients with advanced non-small cell lung cancer.
Ulas A; Turkoz FP; Silay K; Tokluoglu S; Avci N; Oksuzoglu B; Alkis N
PLoS One; 2014; 9(12):e114471. PubMed ID: 25474743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]